Update on the use of montelukast in pediatric asthma

Allergy and Asthma Proceedings

Volumn 27, Issue 4, 2006, Pages 312-318

  Capristo, Carlo ^a,b   Rigotti, Erika ^a,c   Boner, Attilio L ^a,c  

^a Second University of Naples ^*

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE RECEPTOR; MEMBRANE PROTEIN; MONTELUKAST; QUINOLINE DERIVATIVE;

ASTHMA; CHILD; CHRONIC DISEASE; DRUG ANTAGONISM; HUMAN; PRESCHOOL CHILD; REVIEW;

ACETATES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; HUMANS; MEMBRANE PROTEINS; QUINOLINES; RECEPTORS, LEUKOTRIENE;

EID: 33748120159     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2006.27.2883     Document Type: Review

References (93)

1. Kanaoka Y, and Boyce JA. Cysteinyl leukotrienes and their receptors: Cellular distribution and their function in immune and inflammatory responses. J Immunol 173:1503-1510, 2004.
2. Green SA, Malice MP, Tanaka W, et al. Increase in urinary leukotriene LTE4 levels in acute asthma: Correlation with air-flow limitation. Thorax 59:100-104, 2004.
3. Dworski R, Fitzgerald GA, Oates JA, and Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 149:953-959, 1994.
4. Reiss TF, Altman LC, Chervinsky P, at al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 98:528-534, 1996.
5. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics 107:381-390, 2001.
6. Baraldi E, Pasquale F, Bonetto G, et al. Exhaled gas analysis and airway inflammation. Pediatr Pulmonol Suppl 26:16-19, 2004.
7. Malmberg LP, Pelkonen AS, Haahtela T, and Turpeinen M. Exhaled nitric oxide rather than lung function distinguishes preschool children with probable asthma. Thorax 58:494-499, 2003.
8. Piacentini GL, Del Giudice MJ, Bodini A, et al. Exhaled NO reduced on allergen avoidance. Allergy 56:251-252, 2001.
9. Miraglia del Giudice M, Papasso M, Maiello N, et al. Exhaled nitric oxide and atopy in children. J Allergy Clin Immunol 111:193, 2003.
10. Piacentini GL, Bodini A, Costella S, et al. Allergen avoidance is associated with a fall in exhaled nitric oxide in asthmatic children. J Allergy Clin Immunol 104:1323-1324, 1999.
11. Bratton DL, Lanz MJ, Miyazawa N, et al. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study. Pediatr Pulmonol 28:402-407, 1999.
12. Bisgaard H, Loland L, and Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 160:1227-1231, 1999.
13. Ghiro L, Zanconato S, Rampon O, et al. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 20:630-634, 2002.
14. Piacentini GL, Peroni DG, Del Giudice MM, et al. Effect of montelukast on exhaled NO in asthmatic children exposed to relevant allergens. Pediatr Allergy Immunol 13:137-139, 2002.
15. Buchvald F, and Bisgaard H. Comparison of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. Ann Allergy Asthma Immunol 91:309-313, 2003.
16. Strauch E, Moske O, Thoma S, et al. A randomized controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma. Pediatr Res 54:198-203, 2003.
17. Stelmach I, Jerzynska J, and Kuna P. A randomised, double-blind trial of the effect of glucocorticoid, antileukotriene, and beta-agonist treatment on IL-10 serum levels in children with asthma. Clin Exp Allergy 32:264-269, 2002.
18. Stelmach I, Majak P, Jerzynsca J, and Kuna P. The effect of treatment with montelukast on in vitro interleukin-10 production of mononuclear cells of children with asthma. Clin Exp Allergy 35:213-220, 2005.
19. Stelmach I, Jerzynska J, and Kuna A. randomised, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J Allergy Clin Immunol 109:257-263, 2002.
20. Volovitz B, Tabachnik E, Nussinovitch M, et al. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. J Allergy Clin Immunol 104:1162-1167, 1999.
21. Sampson AP, Pizzichini E, and Bisgaard H. Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. J Allergy Clin Immunol 111(suppl 1):S49-S61, 2003.
22. O'Byrne PM. Leukotriene bronchoconstriction induced by allergen and exercise. Am J Respir Crit Care Med 161:S68-S72, 2000.
23. Carraro S, Corradi M, Zanconato S, et al. Exhaled breath condensate cysteynyl leukotrienes are increased in children with exercise-induced bronchoconstriction. J Allergy Clin Immunol 115:764-770, 2005.
24. Carlsen KH, and Carlsen KC. Exercise-induced asthma. Paediatr Respir Rev 3:154-160, 2002.
25. Carlsen KH, Engh G, and Mork M. Exercise-induced bronchoconstriction depends on exercise load. Respir Med 94:750-755, 2000.
26. Leff JA, Busse WW, Pearlman D, et al. Montelukast a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 16:147-152, 1998.
27. Kim JH, Lee SY, Kim HB, et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr Pulmonol 39:162-166, 2005.
28. Villaran C, O'Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 104:547-553, 1999.
29. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomised, double-blind trial. Exercise Study Group. Ann Intern Med 132:97-104, 2000.
30. Peroni DG, Piacentini GL, Ress M, et al. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. Pediatr Allergy Immunol 13:434-437, 2002.
31. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 133:424-428, 1998.
32. Peroni DG, Piacentini GL, Pietrobelli A, et al. The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children. Eur Respir J 20:104-107, 2002.
33. Melo RE, Sole D, and Naspitz CK. Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol 111: 301-307, 2003.
34. Peters SP. Leukotriene receptor antagonists in asthma therapy. J Allergy Clin Immunol 111:562-570, 2003.
35. Bisgaard H. Long-acting beta (2)-agonists in management of childhood asthma: A critical review of the literature. Pediatr Pulmonol 29:221-234, 2000.
36. Vidal C, Fernandez-Ovide E, Pineiro J, et al. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 86:655-658, 2001.
37. Sue-Chu M, Sandsund M, Holand B, and Bjermer L. Montelukast does not affect exercise performance at subfreezing temperature in highly trained non-asthmatic endurance athletes. Int J Sports Med 21:424-428, 2000.
38. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized double-blind trial. Pediatric Montelukast Study Group. JAMA 279: 1181-1186, 1998.
39. Fricker J. New asthma drug proves useful in young children. Lancet 351:1185, 1998.
40. Becker A. Clinical evidence with montelukast in the management of chronic childhood asthma. Drugs 59(suppl 1):29-34, 2000.
41. Sharek PJ, Mayer ML, Loewy L, et al. Agreement among measures of asthma status: A prospective study of low-income children with moderate to severe asthma. Pediatrics 110:797-804, 2002.
42. Teeter JG, and Bleecker ER. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 113:272-277, 1998.
43. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: A randomized, double-blind, crossover study. J Pediatr 138:694-698, 2001.
44. Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA, et al. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. J Allergy Clin Immunol 109:794-799, 2002.
45. Bentur L, Beck R, Shinawi M, et al. Wheeze monitoring in children for assessment of nocturnal asthma and response to therapy. Eur Respir J 21:621-626, 2003.
46. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115:233-242, 2005.
47. Zeiger RS, Szefler SJ, Phillips B, et al. Response to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 117:45-52, 2006.
48. Bukstein DA, Bratton DL, Firriolo KM, et al. Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: A randomised, open-labe, crossover study. J Asthma 40:475-485, 2003.
49. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: Results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Opin 17:96-104, 2001.
50. Williams B, Noonan G, Reiss TF, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 31:845-854, 2001.
51. Karaman O, Sunneli L, Uzuner N, et al. Evaluation of montelukast in 8 to 14 year old children with mild persistent asthma and compared with inhaled corticosteroids. Allergol Immunopathol (Madr) 32:21-27, 2004.
52. Narayanan S, Edelman JM, Berger ML, and Markson LE. Asthma control and patient satisfaction among early pediatric users of montelukast. J Asthma 39:757-765, 2002.
53. Sherman J, Patel P, Hutson A, et al. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma. Pharmacotherapy 21:1464-1467, 2001.
54. Bukstein DA, Luskin AT, and Bernstein A. "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 90:543-549, 2003.
55. Sveum RJ. Childhood asthma. Balancing efficacy and adherence for optimum management. Postgrad Med. 118:43-50, 2005.
56. Carter ER, and Ananthakrishnan M. Adherence to montelukast versus inhaled corticosteroids in children with asthma. Pediatr Pulmonol 36:301-304, 2003.
57. Taussig LM, Wright AL, Holberg CJ, et al. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol 111:661-675, 2003.
58. Roorda RJ, Mezei G, Bisgaard H, and Maden C. Response of preschool children with asthma symptoms to fluticasone propionate. J Allergy Clin Immunol 108:540-546, 2001.
59. Pao CS, and McKenzie SA. Randomized controlled trials of fluticasone in preschool children with intermittent wheeze. Am J Respir Crit Care Med 166:945-949, 2002.
60. Tepper AM, Kofman CD, Szulman GA, et al. Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma. Am J Respir Crit Care Med 171:587-590, 2005.
61. McKean M, and Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev CD001107, 2000.
62. Stevenson EC, Turner G, Heaney LG, et al. Bronchoalveolar lavage findings suggest two different forms of childhood asthma. Clin Exp Allergy 27:1027-1035, 1997.
63. Azevedo I, de Blic J, Scheinmann P, et al. Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants. Modulation by dexamethasone. Am J Respir Crit Care Med 152:1208-1214, 1995.
64. van Schaik SM, Tristram DA, Nagpal IS, et al. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 103:630-636, 1999.
65. Krawiec ME, Westcott JY, Chu HW, et al. Persistent wheezing in very young children is very young children is associated with lower respiratory inflammation. Am J Respir Crit Care Med 163:1338-1343, 2001.
66. Oommen A, and Grigg J. Urinary leukotriene E4 in preschool children with acute clinical viral wheeze. Eur Respir J 21:149-154, 2003.
67. Knorr B, Nguyen HH, Kearns GL, et al. Montelukast dose selection in children ages 2 to 5 years: Comparison of population pharmacokinetics between children and adults. J Clin Pharmacol 41:612-619, 2001.
68. Bisgaard H, and Nielsen KG. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am J Respir Crit Care Med 162:187-190, 2000.
69. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 108:E48, 2001.
70. Straub DA, Minocchieri S, Moeller A, et al. The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest 127:509-514, 2005.
71. Straub DA, Moeller A, Minocchieri S, et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 25:289-294, 2005.
72. Bont L, Steijn M, van Aalderen WM, and Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J 23:414-417, 2004.
73. Bisgaard H, Study Group on montelukast and respiratory syncytial virus. A randomised trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 167:379-383, 2003.
74. Bisgaard H, Gillies J, Groenewald M, and Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: A dose comparison study. Am J Respir Crit Care Med 160:126-131, 1999.
75. Bisgaard H. Montelukast in RSV-bronchiolitis. Am J Respir Crit Care Med 169:542-543, 2004.
76. Bisgaard H, Zielen S, Garcia-Gargia L, et al. Montelukast reduces asthma exacerbations in 2 to 5 year old children with intermittent asthma. Am J Respir Crit Care Med 171:315-322, 2005.
77. Robertson CF, Henry RL, Mellis C, et al. Short course montelukast for intermittent asthma in children: The PRE-EMPT study. Am J Respir Crit Care Med 169:A149, 2004.
78. Price E, Robertson F, Henry L, et al. Short course montelukast for intermittent asthma in children: Economic analysis of the PRE-EMPT study. Eur Respir J 24(suppl 48):310s, 2004.
79. Weinberger M. Montelukast for viral respiratory infection-induced exacerbations of asthma. Am J Respir Crit Care Med 172:783, 2005.
80. Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonists, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 31:77-87, 2001.
81. Cobb DB, Abbott CL, Watson WA, and Fernandez MC. High-dose montelukast exposure in a 3 year-old and 5-year-old child. Vet Hum Toxicol 44:91-92, 2002.
82. Geller M, Melo LR, and Coutinho SV. Successful outcome of montelukast overdosage in an asthmatic child. Ann Allergy Asthma Immunol 84:370, 2000.
83. Drazen JM, Israel E, and O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340: 197-206, 1999.
84. Meyer KA, Arduino JM, Santanello NC, et al. Response to montelukast among subgroups of children aged 2 to 14 years with asthma. J Allergy Clin Immunol 111:757-762, 2003.
85. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta (2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162:75-80, 2000.
86. Strauss L, Hejal R, Galan G, et al. Observations on the effects of aerosolized albuterol in acute asthma. Am J Respir Crit Care Med 155:454-458, 1997.
87. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomised, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 130:487-495, 1999.
88. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109:410-408, 2002.
89. McFadden ER Jr, and Hejal R. Asthma. Lancet 345:1215-1220, 1995.
90. National Asthma Education and Prevention Program report: Guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol 110(suppl):S141-S219, 2002.
91. Pifferi M, Caramella D, Ragazzo V, et al. Montelukast and airway remodeling in children with chronic persistent asthma: An open study. Pediatr Allergy Immunol 15:472-473, 2004.
92. Henderson WR Jr, Chiang GK, Tien YT, and Chi EY. Reversal of allergen-induced airway remodelling by CysLT1 receptor blockade. Am J Respir Crit Care Med 173:718-728, 2006.
93. Lara M, Duan N, Sherbourne C, et al. Differences between child and parent reports of symptoms among Latino children with asthma. Pediatrics 102:E68, 1998.